2021
N‐acylethanolamine‐hydrolysing acid amidase: A new potential target to treat paclitaxel‐induced neuropathy
Toma W, Caillaud M, Patel NH, Tran TH, Donvito G, Roberts J, Bagdas D, Jackson A, Lichtman A, Gewirtz DA, Makriyannis A, Malamas MS, Damaj MI. N‐acylethanolamine‐hydrolysing acid amidase: A new potential target to treat paclitaxel‐induced neuropathy. European Journal Of Pain 2021, 25: 1367-1380. PMID: 33675555, DOI: 10.1002/ejp.1758.Peer-Reviewed Original ResearchConceptsPaclitaxel-induced peripheral neuropathyPaclitaxel-induced mechanical hypersensitivityMechanical hypersensitivitySpinal cordSelective NAAA inhibitorsNAAA inhibitorsPEA levelsDevelopment of PIPNMajor dose-limiting side effectDose-limiting side effectAdministration of palmitoylethanolamidePaclitaxel-induced neuropathyPaclitaxel-treated micePaclitaxel-induced cytotoxicityEvidence of toleranceEffective chemotherapeutic agentIntrinsic rewarding effectsLung tumor cellsNew potential targetsEndogenous palmitoylethanolamidePain aversivenessAcute administrationPeripheral neuropathyControl micePEA administration
2018
Reduced intraepidermal nerve fibre density, glial activation, and sensory changes in HIV type-1 Tat-expressing female mice
Wodarski R, Bagdas D, Paris J, Pheby T, Toma W, Xu R, Damaj M, Knapp P, Rice A, Hauser K. Reduced intraepidermal nerve fibre density, glial activation, and sensory changes in HIV type-1 Tat-expressing female mice. PAIN Reports 2018, 3: e654. PMID: 29922746, PMCID: PMC5999412, DOI: 10.1097/pr9.0000000000000654.Peer-Reviewed Original ResearchIntraepidermal nerve fiber densityDorsal root gangliaNerve fiber densitySensory neuropathyTAT inductionHIV infectionFiber densityFemale miceSpinal cordHIV type 1 (HIV-1) TatIba-1-positive cellsLumbar dorsal root gangliaGlial fibrillary acidic protein immunoreactivityGlial fibrillary acidic protein promoterClinical HIV infectionPaw withdrawal thresholdPaw withdrawal latencyChronic pain statesSpontaneous motor activityImmune cell activationAcidic protein promoterPainful HIVGlial activationPaw withdrawalWithdrawal threshold
2016
The α7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain
Bagdas D, Wilkerson J, Kulkarni A, Toma W, AlSharari S, Gul Z, Lichtman A, Papke R, Thakur G, Damaj M. The α7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain. British Journal Of Pharmacology 2016, 173: 2506-2520. PMID: 27243753, PMCID: PMC4959951, DOI: 10.1111/bph.13528.Peer-Reviewed Original ResearchConceptsPositive allosteric modulatorsNeuropathic painPain modelAntinociceptive effectSpinal cordTail flickChronic constriction injury (CCI) neuropathic pain modelAllosteric agonistDose-dependent antinociceptive effectΑ7 nicotinic ACh receptorsGlial fibrillary acidic proteinNeuropathic pain modelAstrocyte-specific glial fibrillary acidic proteinInflammatory pain modelAcetic acid injectionHot-plate assayEffective pharmacological strategiesNicotinic ACh receptorsNovel therapeutic approachesFibrillary acidic proteinDorsal hornFormalin testPain modulationSubchronic administrationLocus of action